Original Article: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer (BREAKWATER phase 3 trial) nej.md/3ScDaWC #ASCO25 | ASCO

Always good to see OS benefit for our patients affected by metastatic Breast Cancer! OncoAlert

❓So, time for perioperative ChT for biliary tract cancers? #ASCO25 ✅POLCAGB (locally advanced gallbladder ca) neoadj CRT+ChT vs ChT mOS: 21.8 vs 10.1 mo, p=0.006 ✅GAIN (localized or locally advanced BTCs) perioperative GemCis vs surgery plus adjuvant tx mOS: 27.8 vs. 14.6

First-line Sacituzumab + Pembrolizumab improves PFS in 1st Line TNBC. 🚨🔔‼️ Crossover 80% Sacituzumab Offered! Very few patients with prior IO, few who relapsed within 6-12 months. OS looks similar but early days. #bcsm great job Sara Tolaney !!

Finally some POSITIVE studies in Pancreatic Cancer space. Long way to go but some encouraging results...

📈 New 1st-line standard for PIK3CA-mutant HR+/HER2– breast cancer? #ASCO25 #INAVO120 shows that inavolisib + palbociclib + fulvestrant ⌛ Chemo delayed ~2 yrs 📄 Simultaneously in NEJM: 🔗 nejm.org/doi/full/10.10… 👇 OncoAlert ASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Cristiane D Bergerot Nazli Dizman

🚨 New frontline option in PD-L1+ TNBC? 🧪 ASCENT-04 (ASCO 2025): SG + pembrolizumab beats chemo + pembro ⏳ PFS: 11.2 vs 7.8 mo 🔁 DOR: 16.5 vs 9.2 mo 🎯 ORR: 59.7% vs 53.2% ⚠️ AE-related discontinuation: 12% vs 31% 📍Presented by Sara Tolaney 📄 Abstract LBA109 | #ASCO25 👥

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Presented at #ASCO25: In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

Rapid oral abstracts: Congrats to presenters! Ticiana Batista (Leal) with a fabulous discussion Not really practice changing (yet) 🔑 Need more focus on toxicity and subgroups as well as bio markers Computational pathology for the win! #lcsm #ASCO25

Standing ovation at ⁦ASCO⁩ for the Challenge Trial. Take a look at this comparison of the magnitude of the exercise effect from Challenge versus multiple drug effects.

Exercise is medicine. #ASCO25

ASCO SEP breast recommendations I usually tell patients that exercise works just as well as medication, maybe even better.

📢 NIVOPOSTOP phIII: Adding adjuvant nivolumab to CRT post-surgery significantly improves DFS in high-risk LA-SCCHN (HR 0.76; p=0.034). 🎯 3-yr DFS: 63.1% vs 52.5% with CRT alone. 🔑 First improvement over SOC in >20 years! #ASCO2025 #HNSCC #Immunotherapy

Eid is time forgive and come together. Happy Eid Mubarak to all. National beef Biryani.

MRF has completed the construction of the first well of 2025 in village Khursheed Khan Meetlo, Sindh! This well is a lifeline, providing clean water for underprivileged families and livestock who desperately need it. Donate now mikaelrayaanfoundation.org/donate-now #MRF #nonprofit #Donate

The final results from Elicio Therapeutics AMPLIFY trial are in Nature Medicine reinforcing what has been seen with other platforms - a robust T cell response to tumor antigens post-vaccine is associated with delayed #PancreaticCancer recurrence after surgery. nature.com/articles/s4159…

☢️ Finally published the High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy for LS-SCLC. ✅OS 43.5 versus 22.5 mo, (HR 0.68, 95% CI 0.48–0.98, p = 0.037) No more acute or late onset toxicity. ✅ Would you now consider 60 Gy bid the new standard of care? #LCSM

A practice-changing trial in lung cancer. Congrats Patrick Forde Jonathan Spicer MD PhD M.Provencio and all co-authors #lcsm